Metraipolis › archive › dc_74a5defa442f

Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: A PRISMA-compliant Bayesian network meta-analysis — Europe PMC PMID:34138850

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/34138850
DOI
10.1371/journal.pone.0250096
License (as archived)
CC0-1.0
Archived
2026-11-04T02:52:17.916Z
SHA-256 of the archived text
bb902d45da2188cc09b4441dcb77dec2b140002933643a374837ea225253ee1d
Stable URL of this page
https://metraipolis.com/documento/dc_74a5defa442f

How to cite

Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: A PRISMA-compliant Bayesian network meta-analysis — Europe PMC PMID:34138850 — Europe PMC (en), https://europepmc.org/article/MED/34138850 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_74a5defa442f (Metraipolis archive dc_74a5defa442f, sha256 bb902d45da2188cc09b4441dcb77dec2b140002933643a374837ea225253ee1d)
BibTeX
@misc{dc74a5defa442f,
  title = {Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: A PRISMA-compliant Bayesian network meta-analysis — Europe PMC PMID:34138850},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/34138850},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_74a5defa442f; sha256 bb902d45da2188cc09b4441dcb77dec2b140002933643a374837ea225253ee1d},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34138850. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Objective: To search, review, and analyze the efficacy and safety of various anticoagulants from randomized clinical trials (RCTs) of anticoagulants for THA and TKA. Design: PRISMA-compliant Bayesian Network Meta-analysis. Data sources and study selection: The databases of The Medline, Embase, ClinicalTrial, and Cochrane Library databases were searched until March 2017 for RCTs of patients undergoing a THA or TKA. Main outcomes and measures: The primary efficacy measurement was the venous thromboembolism Odds ratio (OR). The safety measurement was the odds ratio of major or clinically relevant bleeding. OR with 95% credibility intervals (95%CrIs) were calculated. Findings were interpreted as associations when the 95%CrIs excluded the null value. Results: Thirty-five RCTs (53787 patients; mean age range, mostly 55-70 years; mean weight range, mostly 55-90 kg; and a higher mean proportion of women than men, around 60%) included the following Anticoagulants categories: fondaparinux, edoxaban, rivaroxaban, apixaban, dabigatran, low-molecular-weight heparin, ximelagatran, aspirin, warfarin. Anticoagulants were ranked for effectiveness as follows: fondaparinux (88.89% ± 10.90%), edoxaban (85.87% ± 13.34%), rivaroxaban (86.08% ± 10.23%), apixaban (68.26% ± 10.82%), dabigatran (41.63% ± 12.26%), low-molecular-weight heparin (41.03% ± 9.60%), ximelagatran (37.81% ± 15.87%), aspirin (35.62% ± 20.60%), warfarin (9.89% ± 9.07%), and placebo (4.56% ± 6.37%). Ranking based on clinically relevant bleeding events was as follows: fondaparinux (14.53% ± 15.25%), ximelagatran (18.93% ± 17.49%), rivaroxaban (23.86% ± 15.14%), dabigatran (28.30% ± 14.18%), edoxaban (38.76% ± 24.25%), low-molecular-weight heparin (53.28% ± 8.40%), apixaban (71.81% ± 10.92%), placebo (76.26% ± 14.61%), aspirin (86.32% ± 25.74%), and warfarin (87.95% ± 11.27%). No statistically significant heterogeneity was observed between trials. Conclusions and relevance: According to our results, all anticoagulant drugs showed some effectiveness for VTE prophylaxis. Our ranking indicated that fondaparinux and rivaroxaban were safer and more effective than other anticoagulant drugs for patients undergoing THA or TKA.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-06-17).
Identificativi: PMID 34138850 · PMCID PMC8211213 · DOI 10.1371/journal.pone.0250096.
Descrittori MeSH principali: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bayes Theorem; Venous Thromboembolism.
Pagina: https://europepmc.org/article/MED/34138850 — https://doi.org/10.1371/journal.pone.0250096. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-04T02:44:49.618Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.